MEISON

MEISON
Name	MEISON

MEISON

MEISON is a proteinaceous factor studied in cellular and developmental biology. It has been characterized through biochemical, genetic, and imaging approaches across model organisms and human tissues, with connections to signaling pathways, transcriptional networks, and cellular architecture. Research on MEISON has implicated it in differentiation programs, tissue homeostasis, and disease processes, and it has been the subject of targeted molecular studies and translational investigations.

Introduction

MEISON was first described in the context of signaling and transcriptional control in studies employing Drosophila melanogaster, Mus musculus, and human cell lines. Early reports linked MEISON to regulators such as Notch signaling pathway, Wnt signaling pathway, Transforming growth factor beta receptor, and components of the MAP kinase cascade. Subsequent investigations connected MEISON to chromatin-associated factors including Polycomb group, SWI/SNF complex, and Mediator complex, and to post-translational modifiers like ubiquitin ligase families and SUMOylation enzymes.

Structure and Molecular Function

MEISON encodes a polypeptide that contains conserved motifs reminiscent of DNA-binding and protein–protein interaction domains found in factors such as C2H2 zinc finger, Homeobox, bHLH domain, and PHD finger proteins. Structural studies using X-ray crystallography and cryo-electron microscopy compared MEISON domains to those in p53, CREB-binding protein, and BRD4, revealing potential interfaces for interaction with nucleic acids and cofactors. Biochemical assays demonstrated that MEISON associates with chromatin through contacts involving nucleosome-binding surfaces analogous to histone H3 recognition modules and interacts with transcription factors like STAT3, NF-κB, and SMAD3. Enzymatic activities reported in vitro include scaffolding for kinase complexes such as Cyclin-dependent kinase 9 and adapter functions for E3 ligases similar to MDM2 and CUL1.

Expression and Regulation

Expression profiling using RNA-seq, microarray, and in situ hybridization across species revealed that MEISON transcripts are enriched in tissues including the neocortex, hippocampus, cardiac myocardium, and developing limb bud. Single-cell transcriptomics placed MEISON within lineages marked by SOX2, PAX6, MYOD1, and GATA4 expression. Transcriptional regulation of MEISON involves promoters responsive to enhancers bound by FOXP2, CREB1, E2F1, and c-Myc, while epigenetic control features marks deposited by EZH2 and DOT1L. Post-transcriptional regulation engages microRNAs such as miR-9, miR-124, and let-7 family members, and RNA-binding proteins including HuR and FMR1 that modulate transcript stability and localization. Proteostasis of MEISON is governed by chaperones like HSP90 and degradation pathways involving the proteasome and autophagy components such as ATG5 and LC3.

Role in Development and Physiology

Functional studies employing gene knockout and overexpression in zebrafish, Xenopus laevis, and mouse models linked MEISON to processes including neurogenesis, cardiogenesis, and myogenesis. Loss-of-function phenotypes resembled perturbations seen in models deficient for Notch signaling pathway, Wnt signaling pathway, and Hedgehog signaling pathway components, with defects in neural progenitor maintenance marked by altered Nestin and Doublecortin expression. In cardiac development, MEISON perturbation affected expression programs driven by NKX2-5 and TBX5 and influenced trabeculation and conduction system formation. In adult physiology, conditional manipulation of MEISON impacted synaptic plasticity markers such as BDNF and electrophysiological properties tied to NMDA receptor function, and modulated metabolic pathways involving AMPK and mTOR signaling.

Clinical Significance and Disease Associations

Clinical and translational research associated alterations in MEISON expression or sequence with disorders including neurodevelopmental delays, congenital heart defects, and certain cancers. Genome-wide association and sequencing studies linked MEISON loci to phenotypes reported in cohorts studied by groups working on autism spectrum disorder, congenital heart disease consortium, and cancer consortia such as The Cancer Genome Atlas and ICGC. Somatic alterations in tumors showed co-occurrence with mutations in TP53, KRAS, and PIK3CA, and expression signatures correlated with outcomes in malignancies like glioblastoma, breast carcinoma, and hepatocellular carcinoma. Neuropsychiatric associations implicated MEISON in pathways overlapping with genes such as NRXN1, SHANK3, and MECP2, with potential relevance to synaptopathies and intellectual disability. Therapeutic interest has explored targeting MEISON-associated complexes using small molecules developed against BET inhibitors, HDAC inhibitors, and kinase inhibitors directed at CDK inhibitors.

Research Tools and Experimental Studies

Tools developed for MEISON research include monoclonal antibodies, fluorescently tagged constructs, CRISPR/Cas9 knockout and knock-in alleles, and transgenic reporter lines in mouse models and Drosophila melanogaster. High-throughput interaction screens used affinity purification coupled to mass spectrometry with comparisons to datasets from BioGRID, STRING, and IntAct. Functional genomics employed CRISPR screens validated against benchmarks like the DepMap platform, and perturb-seq experiments integrated single-cell readouts with perturbations in genes such as SOX2, PAX6, and MYC. Chemical biology approaches tested compounds from libraries inspired by inhibitors of EZH2, BRD4, and CDK9 to modulate MEISON complexes. Imaging studies used super-resolution techniques alongside reporters for actin cytoskeleton and microtubule dynamics to map MEISON subcellular distribution.

Category:Proteins